There was a time when modern medicine was primitive. There were no antibiotics, so every infection took its own course, leading to decline in health. Hypertension and diabetes were largely untreatable. X-ray was new, and remedies had changed but little from medieval times. No one ever embarked on the goodness of preventative treatment, not to speak of predictive medicine, beyond taking a distasteful cod liver oil capsule.
During the last hundred years, modern medicine has undergone a sea change. Just think of it an ever-expanding repertoire of medicines, high-tech procedures, therapies and reams of clinical data to employ when one gets sick. Yet modern medicine remained (in)complete, notwithstanding the therapeutic advances.
READ MORE
Things are now changing thanks to the integration of all such advances, from how a persons diet interacts with ones unique genetic profile to how environmental pollutants affect our thinking, not to speak of preventative medical approaches in health and wellness. The bigperestroikahas begun, and it is poised to transform health care for a growing number of people in the near future. Welcome to a whole new world of personalized, bespoke medicine.
Personalized medicine is, in essence, tailored or customized medical treatment. It treats while keeping in mind the unique, individual characteristics of each patient, which are as distinct as ones fingerprint or signature. It also includes scientific breakthroughs in our understanding of how a persons unique molecular and genetic profile makes them susceptible to certain illnesses. Personalized medicine expands our ability to envisage medical treatments that would not only be effective but also safe for each patient while excluding treatments that may not provide useful objectives.
Personalized medicine is, in simple terms, the use of new methods of molecular scrutiny. It is keyed to help better manage a patients illness or their genetic tendency toward a particular illness or a group of diseases. In so doing, it aims to achieve optimal therapeutic outcomes by helping both clinicians and patients choose a disease management approach that is likely to work best in the context of the patients unique genetic and environmental summary. In other words, it allows to accurately diagnose diseases and their sub-types while prescribing the best form and dose of medication most suited to the given patient.
Personalized, or precision, medicine is not rocket science it is, in essence, an extension of certain traditional approaches to understanding and treating disease. What jazzed up the therapeutic fulcrum of personalized medicine are tools that are more precise. This is what also offers clinicians better insights for selecting a treatment protocol based on a patients molecular profile. Such a patient-specific methodology, as has been practiced for long in certain complementary and alternative medical (CAM) or integrative approaches, not only curtails harmful side effects but also leads to more successful outcomes, including reduced costs in comparison to the current trial-and-error approach to treatment, which has distressingly come to the fore during these extraordinary and unprecedented times of COVID-19.
It is still early days, but the fact remains that personalized medicine has changed the old ways of how we all thought about, identified and managed health issues. As personalized medicine increasingly bids fair to an exciting journey in terms of clinical research and patient care, its impact will only further expand our understanding of medical technology.
What personalized medicine has done is bring about a paradigm shift in our thinking about people in general and also specifically. We all vary from one another what we eat, what others eat, how we react to stress or experience health issues when exposed to environmental factors. It is agreed that such variations play a role in health and disease. It is also being incrementally accepted that certain natural variations found in our DNA can influence our risk of developing a certain disease and how well we could respond to a particular medicine.
All of us are unique individuals, perhaps with the exemption of identical twins, albeit the genomes are unique in them, too. While we are genetically similar, there are small differences in our DNA that are unique, which also makes us distinctive in terms of health, disease and our response to certain medicinal treatments.
Personalized medicine is poised to tap natural variations found in our genes that may play a role in our risk of getting or not getting certain illnesses, along with numerous external factors, such as our environment, nutrition and exercise. Variations in DNA can, likewise, lead to differences in how medications are absorbed, metabolized and used by the body. The understanding of such genetic variations and their interactions with environmental factors are elements that will help personalized medicine clinicians to produce better diagnostics and drugs, and select much better treatments and dosages based on individual needs not as just fixing a pill or two, as is the present-day conventional medical practice.
It is established that a majority of genes function precisely as intended. This gives rise to proteins that play a significant role in biological processes while allowing or helping an individual to grow, adapt and live in their environment. It is only in certain unusual situations, such as a single mutated or malfunctioning gene, that our apple cart is disturbed. This leads to distinct genetic diseases or syndromes such as sickle cell anemia and cystic fibrosis. In like manner, multiple genes acting together can impact the development of a host of common and complex diseases, including our response to medications used to treat them.
New advances will revolutionize bespoke medical treatment with the inclusion of drug therapy as well as recommendations for lifestyle changes to manage, delay the onset of disease or reduce its impact. Not surprisingly, the emergence of new diagnostic and prognostic tools has already raised our ability to predict likely outcomes of drug therapy. In like manner, the expanded use of biomarkers biological molecules that are associated with a particular disease state has resulted in more focused and targeted drug development.
Molecular testing is being expansively used today to identify breast cancer and colon cancer patients who are likely to benefit from new treatments and to preempt recurrences. A genetic test for an inherited heart condition is helping clinicians to determine which course of treatment would maximize benefit and minimize serious side effects while bringing about curative outcomes.
Such complexities exist for asthma and other disorders too. This is precisely where molecular analysis of biomarkers can help us to identify sub-types within a disease while enabling the clinician to monitor their progression, select appropriate medication, measure treatment outcomes and patients response. Future advances may make biomarkers and other tools affordable and allow clinicians to screen patients for relevant molecular variations prior to prescribing a particular medication.
It is already clear that personalized medicine promises three strategic benefits. In terms of preventative medicine, personalized medicine will improve the ability to identify which individuals are predisposed to develop a particular condition. A better understanding of genetic variations could also help scientists identify new disease subgroups or their associated molecular pathways and design drugs to target them. This could also help select patients for inclusion, or exclusion, in late-stage clinical trials. Finally, it will allow to work out the best dosage schedule or combination of drugs for each individual patient.
Yet not everything is hunky-dory for personalized medicine. Critics of precision medicine believe that the whole idea is too much of overhyped razzmatazz, among other things. Proponents, however, argue that when it comes to managing our own health, most of us are used to the idea of taking a one-size-fits-all approach be it medicines, supplements, diets and diagnoses. This may be wrong.
What works, as they put it, for one may be a gaffe for another. As the award-winning oncologist and medical technology innovator, Dr. David B. Agus, author of the groundbreaking bookThe End of Illness, puts it, each patients individual risk factors are based on ones DNA, the environment and a preventative lifestyle plan in response. He begins with simple, profound pointers: How is your sense of smell? and Is your ring finger longer than your middle finger? He explains with statistics-backed guidelines that moving and walking regularly is mandatory because exercising and then sitting is equivalent to smoking cigarettes, while eating and sleeping at consistent hours is imperative because irregularity causes inflammation.
The inference is obvious: We should all understand our physiology and quiz doctors with the thorough, exploratory frame of mind of a gadget buyer. This holds the key to making medicine truly personal, more humane, effective and safe while keeping in mind the individual in us all as unique and distinctive, the sum of the whole not just the parts.
The views expressed in this article are the authors own and do not necessarily reflect Fair Observers editorial policy.
Read more:
The Future of Medicine Is Bespoke - Fair Observer
- 001 F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent [Last Updated On: April 15th, 2010] [Originally Added On: April 15th, 2010]
- 002 F.D.A. Says Millions Got Unapproved Drugs, Should the new bioequivalence and bioanalytical guidelines for 2010, be made more stringent [Last Updated On: April 16th, 2010] [Originally Added On: April 16th, 2010]
- 003 GSK, MedTrust launch iPhone/iPad app for cancer trials [Last Updated On: June 11th, 2010] [Originally Added On: June 11th, 2010]
- 004 GSK, MedTrust launch iPhone/iPad app for cancer trials [Last Updated On: June 11th, 2010] [Originally Added On: June 11th, 2010]
- 005 22 Million Australian Cloud computing initiative to benefit life science researchers [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 006 GE Healthcare announces SaaS Electronic Medical Records Management [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 007 22 Million Australian Cloud computing initiative to benefit life science researchers [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 008 GE Healthcare announces SaaS Electronic Medical Records Management [Last Updated On: June 19th, 2010] [Originally Added On: June 19th, 2010]
- 009 Stem Cell Therapy: Age of Human Cell Engineering is Born [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 010 Using Stem Cells Scientists Grow a Rat Lung, Humans are Next [Last Updated On: June 29th, 2010] [Originally Added On: June 29th, 2010]
- 011 How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 012 How useful would be the Single-patient clinical trials for improving the hopes of Personalized medicine [Last Updated On: August 12th, 2010] [Originally Added On: August 12th, 2010]
- 013 Life Sciences at Oracle Open World 2010 [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 014 ChIP Enrichment Analysis can speed up drug discovery [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 015 GE’s healthymagination initiative lead Smart Patient Room to improve patient safety goes live at Bassett Medical Center [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 016 The SaaS impact on solution selling for ISVs (via Inner Lining) [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 017 Oracle starts the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 018 Life Sciences at Oracle Open World 2010 [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 019 ChIP Enrichment Analysis can speed up drug discovery [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 020 GE’s healthymagination initiative lead Smart Patient Room to improve patient safety goes live at Bassett Medical Center [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 021 The SaaS impact on solution selling for ISVs (via Inner Lining) [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 022 Oracle starts the Oracle Health Sciences Institute (OHSI), in partnership with Sun Labs [Last Updated On: October 11th, 2010] [Originally Added On: October 11th, 2010]
- 023 70% of Pharmaceutical organisations outsource at least one PV activity. This level is expected to increase to 80% by 2012 [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 024 Insurance coverage for healthcare IT software, to protect healthcare IT companies from damages inflicted by their software [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 025 India announce Heart Surgery for $1000 USD [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 026 Indian Healthcare IT market & Oracle’s presence in Indian Healthcare [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 027 70% of Pharmaceutical organisations outsource at least one PV activity. This level is expected to increase to 80% by 2012 [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 028 Insurance coverage for healthcare IT software, to protect healthcare IT companies from damages inflicted by their software [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 029 India announce Heart Surgery for $1000 USD [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 030 Indian Healthcare IT market & Oracle’s presence in Indian Healthcare [Last Updated On: November 7th, 2010] [Originally Added On: November 7th, 2010]
- 031 Harvard Medical Schools new automated safety surveillance system provides faster early warnings in the postmarket evaluation of medical device safety [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 032 SalesForce.com partner introduces CRM for clinical trial management on Force Platform [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 033 Widespread fraud in the Clinical Trial of Drugs is pervasive event in United States [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 034 Scott Stern Kellogg School of Management speaks about “New Drug Development: From Laboratory to Blockbuster to Generic,” [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 035 collaborative clinical trials management software for Central Laboratories [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 036 MNC Pharma tries to capture the $1.9 billion Indian OTC market by selling Drugs through India’s 170000 post offices [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 037 Clinical Trial and Pharmacovigilance process automation [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 038 Microsoft in Clinical Trials Management System (CTMS) and Electronic Data Capture (EDC) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 039 Oracle Business Intelligence Enteprise Edition (OBIEE) for Clinical Trial Management System (CTMS) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 040 trends in the life sciences and pharma research and development outsourcing (RDO) [Last Updated On: November 29th, 2010] [Originally Added On: November 29th, 2010]
- 041 Sanofi-Aventis ties up with Oxford Univ for oncology research in India [Last Updated On: December 17th, 2010] [Originally Added On: December 17th, 2010]
- 042 PharmaNet unveils touch screen capable data capture platform for Phase I Clinical Trials [Last Updated On: December 17th, 2010] [Originally Added On: December 17th, 2010]
- 043 Adverse Events in Hospitals- United States Department of Health Report slams current measures in US hospitals [Last Updated On: December 23rd, 2010] [Originally Added On: December 23rd, 2010]
- 044 IBM Files Application to Patent The Patent [Last Updated On: January 9th, 2011] [Originally Added On: January 9th, 2011]
- 045 How to improve R&D productivity: the pharmaceutical industry’s grand challenge [Last Updated On: February 7th, 2011] [Originally Added On: February 7th, 2011]
- 046 Clinical Trial and Pharmacovigilance process automation [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 047 Microsoft in Clinical Trials Management System (CTMS) and Electronic Data Capture (EDC) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 048 Oracle Business Intelligence Enteprise Edition (OBIEE) for Clinical Trial Management System (CTMS) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 049 trends in the life sciences and pharma research and development outsourcing (RDO) [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 050 Sanofi-Aventis ties up with Oxford Univ for oncology research in India [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 051 PharmaNet unveils touch screen capable data capture platform for Phase I Clinical Trials [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 052 Adverse Events in Hospitals- United States Department of Health Report slams current measures in US hospitals [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 053 IBM Files Application to Patent The Patent [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 054 How to improve R&D productivity: the pharmaceutical industry’s grand challenge [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 055 AstraZeneca Announce Real-World Evidence Data Collaboration [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 056 AstraZeneca Announce Real-World Evidence Data Collaboration [Last Updated On: February 14th, 2011] [Originally Added On: February 14th, 2011]
- 057 Medication adherence improves, When Patients Share Their Stories [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 058 Questions for the CRO [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 059 Clinical Research Sites Struggle With Increasing Trial Complexity yet most depend on, Google (or other search sites) as the primary information tool [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 060 Medication adherence improves, When Patients Share Their Stories [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 061 Questions for the CRO [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 062 Clinical Research Sites Struggle With Increasing Trial Complexity yet most depend on, Google (or other search sites) as the primary information tool [Last Updated On: March 13th, 2011] [Originally Added On: March 13th, 2011]
- 063 Law of the land can help or destroy the Pharmacovigilance system [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 064 Law of the land can help or destroy the Pharmacovigilance system [Last Updated On: March 27th, 2011] [Originally Added On: March 27th, 2011]
- 065 Indian Government’s new dose of strong medicine to bring cheers to Foreign Pharma CEOs who cut their teeth by struggling to convince Indian pharma to change sales practices [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 066 Indian Government’s new dose of strong medicine to bring cheers to Foreign Pharma CEOs who cut their teeth by struggling to convince Indian pharma to change sales practices [Last Updated On: December 18th, 2011] [Originally Added On: December 18th, 2011]
- 067 Drug Reps Soften Their Sales Pitches, as pharma learns from Disney [Last Updated On: January 15th, 2012] [Originally Added On: January 15th, 2012]
- 068 Drug Reps Soften Their Sales Pitches, as pharma learns from Disney [Last Updated On: January 15th, 2012] [Originally Added On: January 15th, 2012]
- 069 Oracle Unveils Oracle® Health Sciences Omics Data Bank as Part of Oracle Health Sciences Translational Research Center [Last Updated On: January 29th, 2012] [Originally Added On: January 29th, 2012]
- 070 Oracle Unveils Oracle® Health Sciences Omics Data Bank as Part of Oracle Health Sciences Translational Research Center [Last Updated On: January 29th, 2012] [Originally Added On: January 29th, 2012]
- 071 One Way to Teach Your Boss About Social Media [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 072 “The Banks Can Do It, Why Can’t Hospitals?” [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 073 Internet on any Display Device, or internet on TV at low cost can it transform Healthcare or Clinical Research [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 074 Is Life Sciences the New Frontier for Analytics? [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 075 Internet on any Display Device, or internet on TV at low cost can it transform Healthcare or Clinical Research [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 076 Is Life Sciences the New Frontier for Analytics? [Last Updated On: February 12th, 2012] [Originally Added On: February 12th, 2012]
- 077 bluebird bio Appoints David Davidson, M.D., as Chief Medical Officer [Last Updated On: February 17th, 2012] [Originally Added On: February 17th, 2012]
- 078 SOCIAL CRM and its Impact on Pharmaceutical Industry [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- 079 privacy controlled social networking to connect patients with caregivers [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]
- 080 SOCIAL CRM and its Impact on Pharmaceutical Industry [Last Updated On: February 19th, 2012] [Originally Added On: February 19th, 2012]